AUTH/3482/3/21: Complainant v GlaxoSmithKline (LinkedIn post about Nucala) – Out of scope of the ABPI Code | PMCPA Case

📊

Key facts

⌄

Case number	AUTH/3482/3/21
Parties	Complainant v GlaxoSmithKline
Allegation	Alleged promotion of Nucala (mepolizumab) on LinkedIn
Complaint received	04 March 2021
Completed	01 December 2021
Applicable Code year	2019
Appeal	No appeal
PMCPA publication	No summary / No report (outwith the scope of the Code)
Clauses cited	Not stated
Sanctions	Not stated

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

⌄

A complaint was made alleging promotion of Nucala (mepolizumab) on LinkedIn.
The matter was assessed by the PMCPA as outwith the scope of the ABPI Code of Practice.

⚖️

⌄

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →